Compare Iron Mountain Inc (IRM) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iron Mountain Inc vs Merck & Co., Inc. — how do they compare? Iron Mountain Inc trades at $113.5 (market cap $34.46B), while Merck & Co., Inc. trades at $142.03 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 10.2× Iron Mountain Inc's market cap, and Iron Mountain Inc pays the higher dividend (2.99%). Which is the better fit depends on your goals — on Pluang, investors hold Iron Mountain Inc for 80 Days and Merck & Co., Inc. for 98 Days on average.
| IRM | MRK | |
|---|---|---|
Market Cap | $34.46B | $351.28B |
Volume | 1,379,608 | 7,969,665 |
Sector | Real Estate | Health |
52-Week High | $133.06 | $156.43 |
52-Week Low | $78.86 | $82.49 |
Typical Hold Time | 80 Days | 98 Days |
Enterprise Value | $53.87B | $398.04B |
Dividend Yield | 2.99% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Iron Mountain (IRM) trades at $115.73, down 0.66% on the day, with a bullish technical signal and strong analyst consensus. The company reported revenue growth to $6.90B in 2025, though net income margin compressed to 2.09%. Recent news highlights expansion in data centers and digital partnerships, while institutional investors like Bank of America and California State Teachers Retirement System increased holdings significantly in Q2 2026.
The outlook remains positive with a consensus price target of $142.75 implying 23% upside, supported by data center pipeline growth and digital cross-selling. Key risks include high debt levels with a debt-to-asset ratio of 79.04% in 2025 and margin pressure from rising interest expenses. Earnings beats in recent quarters reinforce execution strength, but valuation multiples like a P/E of 82.09 demand sustained growth.
Merck (MRK) trades at $142.79, up 0.61% today, with a bearish technical signal but strong fundamental performance. The company reported revenue of $65.01B in 2025 with a net income margin of 28.07%, and recent quarterly EPS have consistently beaten expectations. Merck is actively expanding its pipeline through acquisitions, such as the pending $6.7B purchase of Terns Pharmaceuticals announced in April 2026.
The outlook is supported by solid profitability and analyst optimism, with a consensus price target of $158.78 implying upside. Key risks include integration challenges from acquisitions and competitive pressures in the oncology sector. Cash flow trends show variability, with a projected net cash outflow of $1.2B in 2026 due to significant investing activities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Iron Mountain Inc
Iron Mountain Inc is a record management services provider. The firm is organized as a REIT. Most of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business
Read more on IRM →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
